Download

Full Text

• Lu RM, Hsu HE, Perez SJLP, et al. Current landscape of mRNA technologies and delivery systems for new modality therapeutics. J Biomed Sci. 2024:31. doi: 10.1186/s12929-024-01080-z
• Estapé Senti M, de Jongh Ca, Dijkxhoorn K, et al. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. J Control Release. 2022;341:475–486. doi: 10.1016/j.jconrel.2021.11.042
• Yang M, Zhang Z, Jin P, et al. Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines. Int J Pharm. 2024:650. doi: 10.1016/j.ijpharm.2023.123695
• Shi D, Beasock D, Fessler A, et al. To PEGylate or not to PEGylate: immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev. 2022;180:114079. doi: 10.1016/j.addr.2021.114079
• Ju Y, Lee WS, Pilkington EH, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano. 2022;16:11769–11780. doi: 10.1021/acsnano.2c04543
• Kong YW, Dreaden EC., PEG: will it come back to you? Polyethylene glycol immunogenicity, COVID vaccines, and the case for new PEG derivatives and alternatives. Front Bioeng Biotechnol. 2022;10:1–8. doi: 10.3389/fbioe.2022.879988
• Yao X, Qi C, Sun C, et al. Poly(ethylene glycol) alternatives in biomedical applications. Nano Today. 2023;48:101738. doi: 10.1016/j.nantod.2022.101738
• Nogueira SS, Schlegel A, Maxeiner K, et al. Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery. ACS Appl Nano Mater. 2020;3:10634–10645. doi: 10.1021/acsanm.0c01834
• Tenchov R, Sasso JM, Zhou QA. Pegylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjug Chem. 2023;34:941–960. doi: 10.1021/acs.bioconjchem.3c00174
• Simberg D, Moghimi SM. Anti-Poly(ethylene glycol) (PEG) antibodies: from where are we coming and where are we going. J Nanotheranostics. 2024;5:99–103. doi: 10.3390/jnt5030007
• Kang DD, Hou X, Wang L, et al. Engineering LNPs with polysarcosine lipids for mRNA delivery. Bioact Mater. 2024;37:86–93. doi: 10.1016/j.bioactmat.2024.03.017
• Berger M, Toussaint F, Ben Djemaa S, et al. Poly(N-methyl-N-vinylacetamide): a strong alternative to PEG for lipid-based nanocarriers delivering siRNA. Adv Healthc Mater. 2023;2302712:1–15. doi: 10.1002/adhm.202302712
• Hassanel DNBP, Pilkington EH, Ju Y, et al. Replacing poly(ethylene glycol) with RAFT lipopolymers in mRNA lipid nanoparticle systems for effective gene delivery. Int J Pharm. 2024:665. doi: 10.1016/j.ijpharm.2024.124695
• van Zyl Dg, Mendes LP, Semper RP, et al. Poly(2-methyl-2-oxazoline) as a polyethylene glycol alternative for lipid nanoparticle formulation. Front Drug Delivery. 2024:4. doi: 10.3389/fddev.2024.1383038
• Wilhelmy C, Keil IS, Uebbing L, et al. Polysarcosine-functionalized mRNA lipid nanoparticles tailored for immunotherapy. Pharmaceutics. 2023:15. doi: 10.3390/pharmaceutics15082068
• Berger M, Toussaint F, Ben Djemaa S, et al. Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery. J Control Release. 2023;361:87–101. doi: 10.1016/j.jconrel.2023.07.031
• Kierstead PH, Okochi H, Venditto VJ, et al. The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes. J Control Release. 2015;213:1–9. doi: 10.1016/j.jconrel.2015.06.023
• Giulimondi F, Vulpis E, Digiacomo L, et al. Opsonin-deficient nucleoproteic corona endows UnPEGylated liposomes with stealth properties in vivo. ACS Nano. 2022;16(2):2088–2100. doi: 10.1021/acsnano.1c07687
• Khutoryanskiy VV. Beyond PEGylation: alternative surface-modification of nanoparticles with mucus-inert biomaterials. Adv Drug Deliv Rev. 2018;124:140–149. doi: 10.1016/j.addr.2017.07.015